• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

复方化浊方通过调节自噬和脂质合成信号通路缓解高脂饮食诱导的非酒精性脂肪肝病。

Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.

机构信息

Pharmacology Laboratory, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan 528400, Guangdong Province, China.

Department of Endocrinology, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan 528400, Guangdong Province, China.

出版信息

World J Gastroenterol. 2024 Aug 14;30(30):3584-3608. doi: 10.3748/wjg.v30.i30.3584.

DOI:10.3748/wjg.v30.i30.3584
PMID:39193572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11346146/
Abstract

BACKGROUND

Fanlian Huazhuo Formula (FLHZF) has the functions of invigorating spleen and resolving phlegm, clearing heat and purging turbidity. It has been identified to have therapeutic effects on type 2 diabetes mellitus (T2DM) in clinical application. Non-alcoholic fatty liver disease (NAFLD) is frequently diagnosed in patients with T2DM. However, the therapeutic potential of FLHZF on NAFLD and the underlying mechanisms need further investigation.

AIM

To elucidate the effects of FLHZF on NAFLD and explore the underlying hepatoprotective mechanisms and .

METHODS

HepG2 cells were treated with free fatty acid for 24 hours to induce lipid accumulation cell model. Subsequently, experiments were conducted with the different concentrations of freeze-dried powder of FLHZF for 24 hours. mice were fed a high-fat diet for 8-week to establish a mouse model of NAFLD, and then treated with the different concentrations of FLHZF for 10 weeks.

RESULTS

FLHZF had therapeutic potential against lipid accumulation and abnormal changes in biochemical indicators and . Further experiments verified that FLHZF alleviated abnormal lipid metabolism might by reducing oxidative stress, regulating the AMPKα/SREBP-1C signaling pathway, activating autophagy, and inhibiting hepatocyte apoptosis.

CONCLUSION

FLHZF alleviates abnormal lipid metabolism in NAFLD models by regulating reactive oxygen species, autophagy, apoptosis, and lipid synthesis signaling pathways, indicating its potential for clinical application in NAFLD.

摘要

背景

复方花粉降脂方（FLHZF）具有健脾化痰、清热化浊的功效。在临床应用中已被证实对 2 型糖尿病（T2DM）有治疗作用。非酒精性脂肪性肝病（NAFLD）在 T2DM 患者中经常被诊断出来。然而，FLHZF 对 NAFLD 的治疗潜力及其潜在的保肝机制仍需要进一步研究。

目的

阐明 FLHZF 对 NAFLD 的作用，并探讨其潜在的保肝机制。

方法

用游离脂肪酸处理 HepG2 细胞 24 小时，诱导脂质积累细胞模型。随后，用不同浓度的 FLHZF 干粉处理细胞 24 小时。用高脂饲料喂养小鼠 8 周建立 NAFLD 小鼠模型，然后用不同浓度的 FLHZF 处理 10 周。

结果

FLHZF 对脂质积累和生化指标的异常变化具有治疗潜力。进一步的实验验证，FLHZF 通过减轻氧化应激、调节 AMPKα/SREBP-1C 信号通路、激活自噬和抑制肝细胞凋亡，缓解异常脂质代谢。

结论

FLHZF 通过调节活性氧、自噬、凋亡和脂质合成信号通路，减轻 NAFLD 模型中的异常脂质代谢，表明其在 NAFLD 临床应用中的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/9422ba5204eb/WJG-30-3584-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/769349169b2e/WJG-30-3584-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/bbecf285ad5d/WJG-30-3584-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/f08bc4334235/WJG-30-3584-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/f51ca3f39d02/WJG-30-3584-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/7a87698effa2/WJG-30-3584-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/237b93e5632d/WJG-30-3584-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/a3442ce2ba77/WJG-30-3584-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/ab519cbb922a/WJG-30-3584-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/f67e9394d220/WJG-30-3584-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/9422ba5204eb/WJG-30-3584-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/769349169b2e/WJG-30-3584-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/bbecf285ad5d/WJG-30-3584-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/f08bc4334235/WJG-30-3584-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/f51ca3f39d02/WJG-30-3584-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/7a87698effa2/WJG-30-3584-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/237b93e5632d/WJG-30-3584-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/a3442ce2ba77/WJG-30-3584-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/ab519cbb922a/WJG-30-3584-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/f67e9394d220/WJG-30-3584-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f30a/11346146/9422ba5204eb/WJG-30-3584-g010.jpg

相似文献

1
Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.复方化浊方通过调节自噬和脂质合成信号通路缓解高脂饮食诱导的非酒精性脂肪肝病。
World J Gastroenterol. 2024 Aug 14;30(30):3584-3608. doi: 10.3748/wjg.v30.i30.3584.
2
Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.可可碱通过调节体内外 mTOR 信号通路改善非酒精性脂肪性肝病的肝脂代谢。
Can J Physiol Pharmacol. 2021 Aug;99(8):775-785. doi: 10.1139/cjpp-2020-0259. Epub 2020 Dec 8.
3
Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.康泰脂颗粒通过 AMPK/mTOR 信号通路减轻高脂饮食喂养大鼠和 HepG2 细胞的非酒精性脂肪肝病。
J Immunol Res. 2020 Aug 20;2020:3413186. doi: 10.1155/2020/3413186. eCollection 2020.
4
Autophagy activation by Jiang Zhi Granule protects against metabolic stress-induced hepatocyte injury.姜之颗粒通过自噬激活保护代谢应激诱导的肝细胞损伤。
World J Gastroenterol. 2018 Mar 7;24(9):992-1003. doi: 10.3748/wjg.v24.i9.992.
5
Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways.消脂方通过激活AMPK和PPAR通路调节脂质代谢，从而减轻非酒精性脂肪性肝病。
J Ethnopharmacol. 2024 Jul 15;329:118165. doi: 10.1016/j.jep.2024.118165. Epub 2024 Apr 7.
6
A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway.一种新型的泽泻提取物通过调节 PPARα 信号通路缓解了小鼠的非酒精性脂肪性肝炎。
Biomed Pharmacother. 2024 Jul;176:116908. doi: 10.1016/j.biopha.2024.116908. Epub 2024 Jun 7.
7
Alpha-naphthoflavone attenuates non-alcoholic fatty liver disease in oleic acid-treated HepG2 hepatocytes and in high fat diet-fed mice.α-萘黄酮可减轻油酸处理的 HepG2 肝细胞和高脂饮食喂养小鼠的非酒精性脂肪性肝病。
Biomed Pharmacother. 2019 Oct;118:109287. doi: 10.1016/j.biopha.2019.109287. Epub 2019 Aug 8.
8
Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease.肝自噬在非酒精性脂肪性肝病的发展过程中波动。
Ann Hepatol. 2020 Sep-Oct;19(5):516-522. doi: 10.1016/j.aohep.2020.06.001. Epub 2020 Jun 15.
9
Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease the Sirt1/AMPK and NF-κB signaling pathways.丙烯基异硫氰酸酯通过 Sirt1/AMPK 和 NF-κB 信号通路改善非酒精性脂肪性肝病中的脂质积累和炎症。
World J Gastroenterol. 2019 Sep 14;25(34):5120-5133. doi: 10.3748/wjg.v25.i34.5120.
10
Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.芦丁通过降低肝脏脂质水平和减轻脂质诱导的氧化损伤，在非酒精性脂肪性肝病小鼠模型中表现出肝脏保护作用。
Int Immunopharmacol. 2017 Aug;49:132-141. doi: 10.1016/j.intimp.2017.05.026. Epub 2017 Jun 1.

引用本文的文献

1
Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease.营养素作为代谢功能障碍相关脂肪性肝病中的表观遗传调节剂。
World J Hepatol. 2025 Aug 27;17(8):108182. doi: 10.4254/wjh.v17.i8.108182.
2
Herbal medicine as a potential treatment for non-alcoholic fatty liver disease.草药作为非酒精性脂肪性肝病的一种潜在治疗方法。
World J Gastroenterol. 2025 Mar 7;31(9):100273. doi: 10.3748/wjg.v31.i9.100273.
3
Fanlian Huazhuo formula: A promising therapeutic approach for metabolic associated steatotic liver disease.

本文引用的文献

1
Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet-Induced Obesity.亚油酸乙醇酰胺的给予可减少高脂肪饮食诱导肥胖相关的体重增加、血脂异常和炎症。
Nutrients. 2023 Oct 20;15(20):4448. doi: 10.3390/nu15204448.
2
Mechanisms Behind NAFLD: a System Genetics Perspective.非酒精性脂肪性肝病的发病机制：系统遗传学视角。
Curr Atheroscler Rep. 2023 Nov;25(11):869-878. doi: 10.1007/s11883-023-01158-3. Epub 2023 Oct 9.
3
Integration of Transcriptomics and Lipidomics Profiling to Reveal the Therapeutic Mechanism Underlying (Sangzhi) Alkaloids for the Treatment of Liver Lipid Metabolic Disturbance in High-Fat-Diet/Streptozotocin-Induced Diabetic Mice.
矾莲化浊方：代谢相关脂肪性肝病的一种有前景的治疗方法。
World J Gastroenterol. 2025 Jan 7;31(1):100250. doi: 10.3748/wjg.v31.i1.100250.
4
Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease.矾连化浊方：一种用于代谢性肝病的有前景的草药制剂。
World J Gastroenterol. 2024 Dec 14;30(46):4964-4968. doi: 10.3748/wjg.v30.i46.4964.
5
Potential of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease: A promising future.中药在治疗非酒精性脂肪性肝病中的潜力：前景广阔。
World J Gastroenterol. 2024 Nov 21;30(43):4597-4601. doi: 10.3748/wjg.v30.i43.4597.
6
Gut microbiota in gastrointestinal diseases: Insights and therapeutic strategies.胃肠道疾病中的肠道微生物群：见解与治疗策略。
World J Gastroenterol. 2024 Oct 21;30(39):4329-4332. doi: 10.3748/wjg.v30.i39.4329.
整合转录组学和脂质组学分析以揭示（桑枝）生物碱治疗高脂饮食/链脲佐菌素诱导的糖尿病小鼠肝脏脂质代谢紊乱的潜在治疗机制。
Nutrients. 2023 Sep 8;15(18):3914. doi: 10.3390/nu15183914.
4
Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.四氢巴马汀通过 AMPK-SREBP-1c-Sirt1 信号轴切换脂质代谢改善非酒精性脂肪性肝病的肝脂肪变性。
Phytomedicine. 2023 Oct;119:155005. doi: 10.1016/j.phymed.2023.155005. Epub 2023 Aug 5.
5
Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy.Thrap3 通过抑制 AMPK 介导的自噬促进非酒精性脂肪性肝病。
Exp Mol Med. 2023 Aug;55(8):1720-1733. doi: 10.1038/s12276-023-01047-4. Epub 2023 Aug 1.
6
Zanthoxylum bungeanum amides ameliorates nonalcoholic fatty liver via regulating gut microbiota and activating AMPK/Nrf2 signaling.花椒酰胺通过调节肠道微生物群和激活 AMPK/Nrf2 信号通路改善非酒精性脂肪肝。
J Ethnopharmacol. 2024 Jan 10;318(Pt A):116848. doi: 10.1016/j.jep.2023.116848. Epub 2023 Jul 7.
7
Digeda-4 decoction and its disassembled prescriptions improve dyslipidemia and apoptosis by regulating AMPK/SIRT1 pathway on tyloxapol-induced nonalcoholic fatty liver disease in mice.地丹四逆汤拆方对他丁醇诱导的非酒精性脂肪肝病小鼠脂代谢紊乱及细胞凋亡的影响及其作用机制
J Ethnopharmacol. 2023 Dec 5;317:116827. doi: 10.1016/j.jep.2023.116827. Epub 2023 Jun 20.
8
The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy.乙型肝炎病毒通过不完全自噬促进非酒精性脂肪性肝病的进展。
Free Radic Biol Med. 2023 Aug 1;204:326-336. doi: 10.1016/j.freeradbiomed.2023.05.020. Epub 2023 May 25.
9
NKK20 Alleviates High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease in Mice through Regulating Bile Acid Anabolism.NKK20 通过调节胆汁酸合成缓解高脂饮食诱导的小鼠非酒精性脂肪肝病。
Molecules. 2023 May 12;28(10):4042. doi: 10.3390/molecules28104042.
10
Oxidative stress: The nexus of obesity and cognitive dysfunction in diabetes.氧化应激：肥胖与糖尿病认知功能障碍的关联。
Front Endocrinol (Lausanne). 2023 Apr 3;14:1134025. doi: 10.3389/fendo.2023.1134025. eCollection 2023.